Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Increased Tissue Damage and Lesion Volumes in African Americans with Multiple Sclerosis
Neurol 74:538-544,532, Weinstock-Guttman,B.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Curable Cause of Paraplegia: Spinal Dural Arteriovenous Fistulae
Stroke 39:2756-2759, Aghakhani,N.,et al, 2008
Neurologic Manifestations of Localized Scleroderma: A Case Report and Literature Review
Neurol 71:1538-1545, Kister,I.,et al, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Arch Neurol 64:1426-1432, de Seze,J.,et al, 2007
Clinicopath Conf., Paraneoplastic Cerebellar Degeneration Due to Anti-Yo Antibodies From Breast Cancer
NEJM 356:612-620, Case 4-2007, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Clinicopath Conf, Hyperviscosity Syndrome Due to IgG Multiple Myeloma
NEJM 346:603-610, Case 6-2002, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Euthanasia and Physician-Assisted Suicide Among Patients with Amyotrophic Lateral Sclerosis in the Netherlands
NEJM 346:1638-1644, Veldink,J.H.,et al, 2002
Phenylketonuria Presenting in Adulthood as Progressive Spastic Paraparesis With Dementia
JNNP 71:795-797, Kasim,S.,et al, 2001
Amyotrophic lateral Sclerosis Mimic Syndromes, A Population-Based Study
Arch Neurol 57:109-113, Traynor,B.J.,et al, 2000
A 44-Year-Old Woman with Difficulty Walking
JAMA 284:2632-2639, Iezzoni,L.I., 2000
The Clinical Spectrum of Anti-GAD Antibody-Positive Patients with Stiff-Person Syndrome
Neurol 55:1531-1535, Dalakas,M.C.,et al, 2000
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
A Case-Control and Nerve Biopsy Study of CREST Mutliple Mononeuropathy
Neurol 49:1641-1645, Dyck,P.J.B.,et al, 1997
Idiopathic Granulomatous Angiitis of the CNS Manifesting as Diffuse White Matter Disease
Neurol 49:1696-1699, Finelli,P.F.,et al, 1997
Lymphoproliferative Disorders and Motor Neuron Disease:An Update
Neurol 48:1671-1678, Gordon,P.H.,et al, 1997
Motor Neuron Disease, Lymphoproliferative Disease, and Bone Marrow Biopsy
Muscle & Nerve 19:1334-1337996., Louis,E.D.,et al, 1996
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Pure Motor Hand Weakness
Semin Neurol 16:75-81, Lewis,R.A., 1996
Subacute Leukoencephalitis Caused by CNS Infection with Human Herpesvirus-6 Manifesting as Acute Multiple Sclerosis
Neurol 47:145-148, Carrigan,D.R.,et al, 1996
Is Chronic Respiratory Failure in Neuromuscular Diseases Worth Treating
JNNP 61:1-3, Shneerson,J.M., 1996
Diagnosing Motor Neurone Disease
BMJ 312:650-651, Chancellor,A.M., 1996
Congenital Muscular Dystrophy Syndromes Distinguished by Alkaline and Acid Phosphatase, Merosin, & Dystrophin Staining
Neurol 46:810-814, Connolly,A.M.,et al, 1996